FDA Panel Supports Tazemetostat for Epithelioid Sarcoma

December 18, 2019 – The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously (11-0) in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery. The purpose of the hearing was to discuss data supporting a new drug application (NDA) for an accelerated approval of tazemetostat in this setting, and to determine whether the overall response … (leggi tutto)